Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373204 · ClinicalTrials.gov registry record · Phase 2
Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)
A Phase 2 study, sponsored by Pharmacyclics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00373204 is a Phase 2 study that was terminated before completion, run by Pharmacyclics. The registered enrollment target is 50 participants.
The verdict
NCT00373204, a Phase 2 study, was terminated before completion, sponsored by Pharmacyclics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the addition of motexafin gadolinium (study drug) to standard treatment with docetaxel will improve the response rate in patients with non-small cell lung cancer.
Interventions
- DRUG Motexafin Gadolinium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00373204
The ClinicalTrials.gov registry entry for NCT00373204 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Motexafin Gadolinium is the first listed.
NCT00373204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00373204 about?
NCT00373204 is a clinical study titled "Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)". The purpose of this study is to determine if the addition of motexafin gadolinium (study drug) to standard treatment with docetaxel will improve the response rate in patients with non-small cell lung cancer.
What is the current status of trial NCT00373204?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2006-05. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00373204?
The interventions under investigation include: Motexafin Gadolinium (DRUG).
Who is sponsoring clinical trial NCT00373204?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.